Skip to main navigation Skip to search Skip to main content

Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson’s Disease

  • University of Health Sciences Lahore
  • Rehman Medical Institute
  • Gomal University

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Patients with Parkinson’s disease (PD) present with an advanced form of age-related muscle loss or sarcopenia. However, the search for a biomarker to accurately predict muscle loss in PD remains elusive. We evaluated the biomarkers of neuromuscular junction (NMJ) stability, including c-terminal agrin fragment-22 (CAF22), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) as predictors of muscle wasting and physical capacity in PD. Male, 63—78 years patients of PD, were investigated for physical capacity, handgrip strength (HGS), and circulating biomarkers at the diagnosis and follow-up during rehabilitation 6 months apart. Patients with PD presented with elevated CAF22 and reduced BDNF and GDNF levels, which were partially restored to normal levels with rehabilitation. All three biomarkers showed significant dynamic associations with HGS and indexes of sarcopenia. Logistic regression revealed that the combination of biomarkers levels into a cumulative risk score enhanced the diagnostic accuracy of sarcopenia. In brief, measurements of plasma BDNF, GDNF, and CAF22 may be helpful in timely diagnosis and/or evaluation of sarcopenia.

Original languageEnglish
Pages (from-to)820-829
Number of pages10
JournalJournal of Molecular Neuroscience
Volume72
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • BDNF
  • CAF22
  • GDNF
  • Parkinson’s disease
  • Sarcopenia

Fingerprint

Dive into the research topics of 'Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson’s Disease'. Together they form a unique fingerprint.

Cite this